Goldman Sachs September "Conviction List" Update: US stocks include Vertex Pharmaceuticals (VRTX.US); top picks for European stocks are Rhein, Adyen, and Talanx
Goldman Sachs has updated its "Conviction List" for the US and European markets.
According to the Zhihong Finance APP, as autumn arrives, Goldman Sachs has updated its "Conviction List" for the US and European markets, providing investors with guidance on stocks that are currently the most favored. In this adjustment, a large biotech stock has been newly added to the US list, while three new names have joined the European list.
US List: Vertex Pharmaceuticals Added, Interactive Brokers Removed
In the US market, Goldman Sachs included Vertex Pharmaceuticals (VRTX.US) on the Conviction List and removed Interactive Brokers (IBKR.US). After the adjustment, the list retains 23 stocks.
Analyst Salveen Richter believes that Vertex Pharmaceuticals, a major biotechnology company, "has a solid foundation for long-term growth as it is capturing opportunities worth potentially several billion dollars across as many as five areas," including cystic fibrosis, pain treatment, kidney disease, and hematology. Additionally, the proposed acquisition of Crinetics (CRNX.US) will further strengthen its fifth key pillar in endocrinology.
Other stocks on the US market list include Estée Lauder (EL.US), Wells Fargo (WFC.US), UnitedHealth (UNH.US), Delta Air Lines (DAL.US), ConocoPhillips (COP.US), Microsoft (MSFT.US), and Block (XYZ.US).
European List: Rhein, Adyen and Talanx Added, Four Stocks Removed
In the European market, Goldman Sachs has added German energy giant Rhein, Dutch payment company Adyen, and German insurance company Talanx. At the same time, it removed Enel, the Italian national power company, UK remittance platform Wise, Hannover Reinsurance, and German e-commerce platform Zalando.
Analyst Alberto Gandolfi stated that Rhein, after acquiring a majority stake in Amprion, is transitioning "from a power producer to a vertically integrated energy giant," and its stock is likely to experience a valuation reappraisal. Gandolfi's forecast for 2031 earnings per share is about 25% higher than both company guidance and market consensus, with an estimated average annual growth rate of around 17% until 2031. He raised the target price by 6%, maintained a "Buy" rating, and sees a potential upside of 27%.
Goldman Sachs believes Adyen's technology stack remains a key differentiator, with its forecast for Adyen's 2027–2029 EBITDA 4% to 6% higher than the market consensus. The firm also stated that Talanx’s international retail business is an underestimated growth engine.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US LNG exports surged to the second-highest level in history in October, with Europe accounting for 60% of demand
In October, U.S. LNG exports reached 7.92 million metric tons, only slightly below the record high of 8.01 million metric tons set in April this year, and saw a significant month-on-month increase from 7.12 million metric tons in September. Europe continues to expand its purchases of U.S. LNG, with its share surging 8 percentage points from the previous month to 60%. Analysts point out that Europe's underground gas storage facilities are nearly full; if temperatures in the Northern Hemisphere remain normal this winter, high global inventories may put downward pressure on prices.
BUZZ-Vertex Pharmaceuticals shares rise after raising 2026 revenue forecast
Tenuis: Apple achieves growth in most markets in the fourth fiscal quarter
Palantir's Q3 revenue doubles, U.S. commercial income surpasses government income for the first time, full-year guidance significantly raised | Earnings Report Insights
Palantir’s Q3 revenue reached $2.313 billion, marking a 96% year-on-year increase and surpassing the market expectation of $2.18 billion. U.S. commercial revenue stood at $984 million, soaring 148% year-on-year and exceeding the expected $937 million. For the first time, it surpassed U.S. government revenue, which was $953 million. Adjusted earnings per share were $0.44, higher than the estimated $0.41. The company raised its full-year revenue forecast to between $8.53 billion and $8.534 billion, above the market consensus of $8.2 billion.
Crypto prices
More
